abbv-903
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 3, 2023 (NCT05691699)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Replicase polyprotein 1abINHIBITOR
Replicase polyprotein 1ab inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06078202 | Phase 1 | Oct 5, 2023 | AbbVie |
| NCT06009237 | Phase 1 | Aug 23, 2023 | AbbVie |
| NCT05995366 | Phase 1 | Aug 18, 2023 | AbbVie |
| NCT05895266 | Phase 1 | Jun 23, 2023 | AbbVie |
| NCT05836506 | Phase 1 | Apr 18, 2023 | AbbVie |
| NCT05691699 | Phase 1 | Jan 3, 2023 | AbbVie |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 6 | 6 | 1 | 2023 |
1 organizations
Page 1 / 1